Schedule 13G ownership disclosure

Phathom Pharmaceuticals Inc

Common Stock, par value $0.0001 per share · CUSIP: 71722W107

Event date: 2025-08-28

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Carlyle Group Inc.

    Shares: 3,496,808.00 · Class: 4.9%

  • Carlyle Holdings I GP Inc.

    Shares: 3,496,808.00 · Class: 4.9%

  • Carlyle Holdings I GP Sub L.L.C.

    Shares: 3,496,808.00 · Class: 4.9%

  • Carlyle Holdings I L.P.

    Shares: 3,496,808.00 · Class: 4.9%

  • CG Subsidiary Holdings L.L.C.

    Shares: 3,496,808.00 · Class: 4.9%

  • TC Group, L.L.C.

    Shares: 3,496,808.00 · Class: 4.9%

  • Carlyle Investment Management L.L.C.

    Shares: 3,496,808.00 · Class: 4.9%

  • Carlyle Genesis UK LLC

    Shares: 3,496,808.00 · Class: 4.9%

  • Abingworth LLP

    Shares: 3,496,808.00 · Class: 4.9%

  • Abingworth Bioventures 8 LP

    Shares: 2,061,702.00 · Class: 2.9%

  • Abingworth Bioventures VII LP

    Shares: 1,435,106.00 · Class: 2.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001641172-25-025812
Form type
SCHEDULE 13G/A
Filer
Carlyle Group Inc.
CIK
CIK 1527166
Filed
Aug 28, 2025
Reporting period
Aug 28, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub